Cargando…
Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia
Thyroid hormones have important effects on cellular development, growth, and metabolism and are necessary for the healthy function of almost all tissues. Hyperthyroid patients with excess thyroid hormone levels experience tachycardia, fatigue, muscle wasting, and osteoporosis. However, although high...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613055/ https://www.ncbi.nlm.nih.gov/pubmed/28865063 http://dx.doi.org/10.1007/s40265-017-0791-4 |
_version_ | 1783266173681401856 |
---|---|
author | Jakobsson, Tomas Vedin, Lise-Lotte Parini, Paolo |
author_facet | Jakobsson, Tomas Vedin, Lise-Lotte Parini, Paolo |
author_sort | Jakobsson, Tomas |
collection | PubMed |
description | Thyroid hormones have important effects on cellular development, growth, and metabolism and are necessary for the healthy function of almost all tissues. Hyperthyroid patients with excess thyroid hormone levels experience tachycardia, fatigue, muscle wasting, and osteoporosis. However, although high thyroid hormone levels have adverse effects, efforts have been made to harness the beneficial effects, such as reduced serum low-density lipoprotein (LDL) cholesterol levels, elevated basal metabolic rate, and weight loss. Thyroid hormones interact with nuclear thyroid hormone receptors (TRs), and cholesterol levels are reduced through TRβ, whereas extrahepatic adverse actions are primarily connected to TRα. Thus, to develop a useful compound for clinical use, efforts have been focusing on developing compounds with isomer-specific functions based on the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRβ specific. In this short review, we discuss the development of the early thyromimetics that enabled, through modern molecular techniques, the progress towards improved design of TRβ-selective thyromimetics. We also address the early promise shown in human clinical trials and the current status of these drugs and other emerging compounds. |
format | Online Article Text |
id | pubmed-5613055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-56130552017-10-10 Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia Jakobsson, Tomas Vedin, Lise-Lotte Parini, Paolo Drugs Leading Article Thyroid hormones have important effects on cellular development, growth, and metabolism and are necessary for the healthy function of almost all tissues. Hyperthyroid patients with excess thyroid hormone levels experience tachycardia, fatigue, muscle wasting, and osteoporosis. However, although high thyroid hormone levels have adverse effects, efforts have been made to harness the beneficial effects, such as reduced serum low-density lipoprotein (LDL) cholesterol levels, elevated basal metabolic rate, and weight loss. Thyroid hormones interact with nuclear thyroid hormone receptors (TRs), and cholesterol levels are reduced through TRβ, whereas extrahepatic adverse actions are primarily connected to TRα. Thus, to develop a useful compound for clinical use, efforts have been focusing on developing compounds with isomer-specific functions based on the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRβ specific. In this short review, we discuss the development of the early thyromimetics that enabled, through modern molecular techniques, the progress towards improved design of TRβ-selective thyromimetics. We also address the early promise shown in human clinical trials and the current status of these drugs and other emerging compounds. Springer International Publishing 2017-09-02 2017 /pmc/articles/PMC5613055/ /pubmed/28865063 http://dx.doi.org/10.1007/s40265-017-0791-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Leading Article Jakobsson, Tomas Vedin, Lise-Lotte Parini, Paolo Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia |
title | Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia |
title_full | Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia |
title_fullStr | Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia |
title_full_unstemmed | Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia |
title_short | Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia |
title_sort | potential role of thyroid receptor β agonists in the treatment of hyperlipidemia |
topic | Leading Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613055/ https://www.ncbi.nlm.nih.gov/pubmed/28865063 http://dx.doi.org/10.1007/s40265-017-0791-4 |
work_keys_str_mv | AT jakobssontomas potentialroleofthyroidreceptorbagonistsinthetreatmentofhyperlipidemia AT vedinliselotte potentialroleofthyroidreceptorbagonistsinthetreatmentofhyperlipidemia AT parinipaolo potentialroleofthyroidreceptorbagonistsinthetreatmentofhyperlipidemia |